JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129
SHANGHAI,Sept. 27,2021 -- JW Therapeutics (HKEx: 2126),an innovative biotechnology company focused on developing,manufacturing and commercializing cell immunotherapy products,today announced that it has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a clinical trial of BCMA-targeted Chimeric Antigen Receptor (CAR) T cell JWCAR129 in treating relapsed or refractory multiple myeloma (R/R MM).
Multiple myeloma (MM) is an incurable blood cancer that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells. Although treatment may result in remission,unfortunately,patients will most likely relapse. While some patients with multiple myeloma have no symptoms at all,most patients are diagnosed due to symptoms that can include bone problems,low blood counts,calcium elevation,kidney problems or infections. Patients who relapse after treatment with standard therapies,including protease inhibitors and immunomodulatory agents,have poor prognoses and few treatment options available. As a result,there is a significant unmet need for patients with R/R MM.
References:
American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: https://www.cancer.net/cancer-types/multiple-myeloma/introduction. Accessed November 2020.
Abdi J,Chen G,Chang H,et al. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4:2186–2207.
American Cancer Society. Multiple myeloma: early detection,diagnosis and staging. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8740.00.pdf. Accessed November 2020.
Kumar SK,Lee JH,Lahuerta JJ,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149-57.
About JW Therapeutics
JW Therapeutics (HKEx: 2126) is an innovative biotechnology company focusing on developing,manufacturing and commercializing cell immunotherapy products. Co-founded by Juno Therapeutics (a Bristol Myers Squibb company) and WuXi AppTec in 2016,JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The company has built a top world-class platform for technology and product development in cell immunotherapy,as well as a promising product pipeline covering both hematologic malignancies and solid tumors,to bring the hope of a cure for Chinese and global patients,and to lead the healthy and standardized development of China's cell immunotherapy industry. For more information,please visit www.jwtherapeutics.com.
Forward-Looking Statements
The forward-looking statements are based on the management's expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties,include those discin ussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted,the Company is providing this information as of the date it publicized,and expressly disclaims any duty to update information contained in the issues and relevant information,or provide any explanation. For detailed information,please visit the company website: www.jwtherapeutics.com/en/forward-looking-statements/.
